GLX351322, a Novel NADPH Oxidase 4 Inhibitor, Attenuates TMJ Osteoarthritis by Inhibiting the ROS/MAPK/NF-κB Signaling Pathways
Oxidative Medicine and Cellular Longevity · 30.01.2023 · 2023 · 1-13
DOI: 10.1155/2023/1952348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oxidative Medicine and Cellular Longevity, erschienen am 30.01.2023. Verfasst von Jinze Zhen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Surgery, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, National Clinical Research Center fo…. Hauptthemen laut MEDLINE: NADPH Oxidase 4, NF-kappa B, Osteoarthritis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Sailing Program, Clinical Research Plan of SHDC, Program of Shanghai Academic/Technology Research Leader.
Abstract (Originalsprache)
As a degenerative disease in joints, temporomandibular joint osteoarthritis (TMJOA) is characterized by progressive cartilage degradation, subchondral bone remodeling, and chronic synovitis, severely undermining functions and quality of life in patients. NADPH oxidase 4 (NOX4) contributes to reactive oxygen species (ROS) production and inflammatory pathway activation in osteoarthritis, which has attracted increasing attention in research in recent years. GLX351322 (GLX), a novel NOX4 inhibitor, exerts a protective effect on chondrocytes. However, whether it has a therapeutic effect on ROS production and inflammatory responses in synovial macrophages remains to be evaluated. In this study, we examined the effect of GLX on LPS-induced ROS production and inflammatory responses in vitro and on complete Freund’s adjuvant (CFA)-induced TMJ inflammation in vivo. We found that GLX could depress LPS-induced intracellular ROS production and inflammatory response without cytotoxicity by inhibiting the ROS/MAPK/NF-κB signaling pathways. In line with in vitro observations, GLX markedly attenuated the synovial inflammatory reaction in the TMJ, thus protecting the condylar structure from severe damage. Taken together, our results suggest that GLX intervention or NOX4 inhibition is a promising curative strategy for TMJOA and other inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oral Surgery, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Ninth People's Hospital, College of Stomatol…
ORCID-Profile: Xuzhuo Chen, Weifeng Xu, Shanyong Zhang
Förderung
- Shanghai Sailing Program
- Clinical Research Plan of SHDC
- Program of Shanghai Academic/Technology Research Leader
- National Natural Science Foundation of China
Zitieren
APA
Zhen, J., Chen, X., Mao, Y., Xie, X., Chen, X., Xu, W., & Zhang, S. (2023). GLX351322, a Novel NADPH Oxidase 4 Inhibitor, Attenuates TMJ Osteoarthritis by Inhibiting the ROS/MAPK/NF-κB Signaling Pathways. Oxidative Medicine and Cellular Longevity, 2023, 1-13. https://doi.org/10.1155/2023/1952348
Vancouver
Zhen J, Chen X, Mao Y, Xie X, Chen X, Xu W, et al. GLX351322, a Novel NADPH Oxidase 4 Inhibitor, Attenuates TMJ Osteoarthritis by Inhibiting the ROS/MAPK/NF-κB Signaling Pathways. Oxidative Medicine and Cellular Longevity. 2023;2023:1-13. doi:10.1155/2023/1952348
BibTeX
@article{Zhen2023,
author = {Zhen, Jinze and Chen, Xinwei and Mao, Yi and Xie, Xinru and Chen, Xuzhuo and Xu, Weifeng and Zhang, Shanyong},
title = {GLX351322, a Novel NADPH Oxidase 4 Inhibitor, Attenuates TMJ Osteoarthritis by Inhibiting the ROS/MAPK/NF-κB Signaling Pathways},
journal = {Oxidative Medicine and Cellular Longevity},
year = {2023},
volume = {2023},
pages = {1--13},
doi = {10.1155/2023/1952348}
}
EUVIMED